Rhythm Pharmaceuticals RYTM 深 沪
已收盘 12-12 16:00:00 美东时间
113.56
-4.060
-3.45%
华盛通- 最 高119.58
- 今 开119.58
- 成交量 174.34万股
- 最 低 109.59
- 昨 收 117.62
- 总市值 72.25亿
- 52周最高 122.20
- 市盈率 静 --
- 换手率 2.74%
- 52周最低 45.905
- 委 比 98.81%
- 总股本 6362.15万
- 历史最高 122.20
- 量 比 1.48
- 振 幅 8.49%
- 历史最低 3.04
- 每 手 1
- 风险率 21.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
12-12 10:24
Rhythm Pharmaceuticals To Unveil Preliminary Phase 2 Data For Setmelanotide In Prader–Willi Syndrome On December 11 At 8:00am ET
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a
12-11 05:02
How Is The Market Feeling About Rhythm Pharmaceuticals Inc?
Rhythm Pharmaceuticals Inc's (NYSE:RYTM) short interest as a percent of float h...
12-02 03:00
美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
11-26 10:07
Citigroup Initiates Coverage On Rhythm Pharmaceuticals with Buy Rating, Announces Price Target of $136
Citigroup analyst Samantha Semenkow initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy rating and announces Price Target of $136.
11-25 22:16
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results
Septerna reported key advancements in its third quarter 2025, including the selection of SEP-479 as a next-generation PTH1R agonist for hypoparathyroidism and initiating the Phase 1 trial for SEP-631 targeting mast cell diseases. With a strong financial position of $561.6 million, the company expects to fund operations into at least 2029, supporting its pipeline progress and strategic milestones.
11-10 12:00
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
Phase 3 TRANSCEND trial results demonstrate that setmelanotide significantly reduces BMI in patients with acquired hypothalamic obesity, particularly when used with GLP-1 therapy, achieving -27.1% and -19.0% placebo-adjusted reductions. The treatment also shows meaningful improvements in cardiometabolic parameters and patient-reported outcomes, highlighting its potential to transform lives.
11-10 12:00
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
